Evidence-graded answer
Is it safe to take GLP-1 long-term?
Liraglutide has 15+ years of post-marketing data (Victoza approved 2010). Semaglutide has 8+ years (Ozempic approved 2017). No new class-wide safety signals have emerged in extended follow-up. Chronic use is the FDA-approved indication for both T2D and obesity.
SELECT (NEJM 2023, 17,604 patients) followed semaglutide-treated patients for a mean 39.8 months with sustained cardiovascular benefit and no new safety concerns.
Pancreatitis and medullary thyroid cancer signals raised in early surveillance remain contested in the literature. A 2023 JAMA disproportionality analysis (Sodhi et al.) reported elevated GI adverse-event odds; CVOT meta-analyses do not show statistically significant pancreatitis increase. Patients with personal or family history of MTC or MEN-2 should avoid GLP-1.
Monitoring labs at 6 and 12 months (kidney function, lipase, thyroid if family history of MTC) are standard practice. Long-term effects on lean mass and bone density continue to be studied; resistance training plus 1.2-1.6 g/kg protein is the standard mitigation.
Source: SELECT — Semaglutide and Cardiovascular Outcomes, NEJM 2023